Clinical Trials on Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

Total 3352 results

Fred Hutchinson Cancer Center

Terminated

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Recurrent Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Burkitt Lymphoma | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Acute Leukemia in Remission | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia and other conditions

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

National Longitudinal Cohort of Hematological Diseases (NICHE)

Lymphoma | Acute Myeloid Leukemia | Leukemia | Hemophilia A | Hemophilia B | Hemophilia | Multiple Myeloma | Myelodysplastic Syndrome | Bone Marrow Transplantation | MDS | Aplastic Anemia | Bleeding Disorder | Myeloma, Multiple | Myelomas, Multiple | Leukemias, Acute Myeloid | Myeloid Leukemias, Acute | Hemophilia As | Hemophilia... and other conditions

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma and other conditions

United States
Asan Medical Center

Terminated

Chronic Myelod Leukemia Registry at Asan Medical Center

Leukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated Phase

Korea, Republic of
University of Utah

Terminated

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Primary Myelofibrosis | Anemia | Thrombocytopenia | Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | IDH2 Gene Mutation | IDH1 Gene Mutation | Secondary Myelofibrosis | ASXL1 Gene Mutation | EZH2 Gene Mutation

United States
University Hospital, Antwerp

Unknown

Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myeloid Leukemia

Belgium
National Cancer Institute (NCI)

Terminated

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Celgene

Completed

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Melanoma | Sarcoma | Neoplasms | Lymphoma | Renal Cell Carcinoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia | Breast Cancer | Small Cell Lung Cancer | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Non-Small Cell Lung Cancer | Osteosarcoma | Glioblastoma Multiforme | Metastatic Breast... and other conditions

United States
Nanfang Hospital of Southern Medical University

Recruiting

Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML (Case-Only)

Chronic Myeloid Leukemia in Myeloid Blast Crisis | Chronic Myeloid Leukaemia Transformation | Chronic Myeloid Leukemia - Accelerated Phase | Chronic Myeloid Leukemia in Lymphoid Blast Crisis

China
National Cancer Institute (NCI)

Terminated

Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Hodgkins Lymphoma

United States
Exelixis

Terminated

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

Chronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

United States
Bristol-Myers Squibb

Completed

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Myeloid Leukemia, Chronic, Accelerated Phase

Australia, Canada, France, Germany, Italy, Korea, Republic of, Taiwan, Thailand, United States, Spain, Austria, Denmark, Belgium, Sweden, Switzerland, Netherlands, Peru, South Africa, Philippines, Singapore, Russian Federation, Br... and more
Assistance Publique - Hôpitaux de Paris

Completed

Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive (AFR07)

Blast Crisis | Philadelphia Chromosome | Leukemia, Lymphocytic, Acute | Leukemia, Myeloid, Chronic

France
Wuhan Createrna Science and Technology Co., Ltd

Not yet recruiting

Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)
BioCryst Pharmaceuticals

Terminated

BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy (REDEEM-2)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Malaysia, South Africa, Korea, Republic of
AKARI Therapeutics

Enrolling by invitation

Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms (CONSENTII)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States
Alexion Pharmaceuticals, Inc.

Completed

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Taiwan, Thailand, Korea, Republic of, Japan, Malaysia, Brazil, Germany, Israel, Czechia, Netherlands, Greece, United Kingdom, Canada, Poland
Ra Pharmaceuticals, Inc.

Terminated

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Australia, Canada, Finland, Germany, Hungary, New Zealand, United Kingdom
Medical College of Wisconsin

Recruiting

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Leukemia | Burkitt Lymphoma | Lymphoblastic Lymphoma | Myelodysplasia | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Chronic Myelogenous Leukemia - Chronic Phase | Chronic Myelogenous Leukemia, Accelerated Phase | Biphenotypic Acute Leukemia | Burkitt Leukemia | Chronic... and other conditions

United States
ADARx Pharmaceuticals, Inc.
ADARx Australia Pty Ltd

Recruiting

Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Australia
NovelMed Therapeutics

Not yet recruiting

Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH - Paroxysmal Nocturnal Hemoglobinuria
Hoffmann-La Roche
Chugai Pharmaceutical

Active, not recruiting

Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria (COMPOSER)

Paroxysmal Hemoglobinuria, Nocturnal

France, Korea, Republic of, Italy, Japan, Germany, Hungary, Netherlands
Alexion Pharmaceuticals, Inc.

Completed

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Italy, United States, Taiwan, Thailand, Brazil, Russian Federation, United Kingdom, Belgium, Canada, Korea, Republic of, Poland, Malaysia, Japan, Czechia, Spain, Germany, Austria, France, Serbia, Mexico, Sweden, Estonia, Singapore, Ar... and more
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy (APPOINT-PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

China, Germany, Singapore, Korea, Republic of, Italy, United Kingdom, Malaysia, France
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (APPLY-PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Italy, Japan, Taiwan, Germany, France, United Kingdom, Spain, Korea, Republic of, Czechia, Brazil, Netherlands, United States
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, United States, Italy
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Hong Kong, Hungary, Korea, Republic of, Malaysia, United Kingdom
Longbio Pharma

Recruiting

A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants

Paroxysmal Nocturnal Hemoglobinuria (PNH)

China
BioCryst Pharmaceuticals

Terminated

BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Hungary, France, Italy, Spain
Alexion Pharmaceuticals, Inc.

Available

Danicopan Early Access Program

Paroxysmal Nocturnal Hemoglobinuria | PNH | Extravascular Hemolysis
AKARI Therapeutics
Radboud University Medical Center

Completed

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Paroxysmal Nocturnal Haemoglobinuria (PNH)

Netherlands
Radboud University Medical Center
Universitaire Ziekenhuizen KU Leuven

Completed

Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections (PIRAÑA)

Acute Graft Versus Host Disease | Allogeneic Stem Cell Transplant | Acute Myeloid Leucaemia | Myelo Dysplastic Syndrome

Belgium, Netherlands
Seagen Inc.

Completed

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Acute Myeloid Leukemia | Solid Tumors | Acute Lymphoid Leukemia | Anemia, Refractory, With Excess of Blasts

United States
Skyline Diagnostics BV
Illumina, Inc.

Terminated

Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler

Acute Myeloid Leukemia (AML) | Acute Promyelocytic Leukemia (APL) | Refractory Anemia With Excess of Blasts (RAEB)

United States, Germany, Netherlands, United Kingdom
Masonic Cancer Center, University of Minnesota

Terminated

Stem Cell Transplant for Hematological Malignancy

Multiple Myeloma | AML | MDS | Non-hodgkin's Lymphoma | Leukemia, Lymphocytic, Acute | Hodgkin's Disease | Leukemia, Myeloid, Chronic | Leukemia, Lymphocytic, Chronic | JMML

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
Ariad Pharmaceuticals

Completed

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Japan
Ariad Pharmaceuticals

Approved for marketing

Expanded Access Program of Ponatinib

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

United States
ChemGenex Pharmaceuticals

Terminated

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Myeloid Leukemia, Chronic, Chronic-Phase | Myeloid Leukemia, Chronic | Myeloid Leukemia, Chronic, Accelerated-Phase | Blast Phase

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia

Japan
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent... and other conditions

United States, Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 Positive

United States
Incyte Biosciences Benelux

Completed

Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

Chronic Myeloid Leukemia | CML | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Ph+ ALL

Belgium
Merck Sharp & Dohme LLC

Terminated

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Chronic Myelogenous Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Bristol-Myers Squibb

Completed

Rollover Study of BMS-354825 in Patients With CML and Ph+ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Acute Leukemia | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Systemic Mastocytosis | Recurrent Hematologic Malignancy | Hairy Cell Leukemia | Chronic... and other conditions
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
Andrew Rezvani
National Institutes of Health (NIH); Pharmacyclics LLC.

Completed

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Hematopoietic Cell Transplantation Recipient | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Biphenotypic Leukemia

United States
Novartis Pharmaceuticals

Completed

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Philadelphia Positive Chronic Myeloid Leukemia

United States, Germany, United Kingdom, France, Italy
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan

Clinical Trials on Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations